198 related articles for article (PubMed ID: 30137485)
1. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.
Fagerli KM; Kearsley-Fleet L; Mercer LK; Watson K; Packham J; Symmons DPM; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):80-85. PubMed ID: 30137485
[TBL] [Abstract][Full Text] [Related]
2. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
[TBL] [Abstract][Full Text] [Related]
3. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
4. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
6. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
Mercer LK; Green AC; Galloway JB; Davies R; Lunt M; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2012 Jun; 71(6):869-74. PubMed ID: 22241900
[TBL] [Abstract][Full Text] [Related]
7. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
8. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.
Hellgren K; Ballegaard C; Delcoigne B; Cordtz R; Nordström D; Aaltonen K; Gudbjornsson B; Love TJ; Aarrestad Provan S; Sexton J; Zobbe K; Kristensen LE; Askling J; Dreyer L
Rheumatology (Oxford); 2021 Aug; 60(8):3656-3668. PubMed ID: 33401297
[TBL] [Abstract][Full Text] [Related]
9. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer LK; Davies R; Galloway JB; Low A; Lunt M; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2013 Jan; 52(1):91-8. PubMed ID: 23238979
[TBL] [Abstract][Full Text] [Related]
10. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.
Cordtz RL; Askling J; Delcoigne B; Smedby KE; Baecklund E; Ballegaard C; Isomäki P; Aaltonen K; Gudbjornsson B; Love TJ; Provan SA; Michelsen B; Sexton J; Dreyer L; Hellgren K
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36564101
[TBL] [Abstract][Full Text] [Related]
11. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.
Strangfeld A; Hyrich K; Askling J; Arkema E; Davies R; Listing J; Neovius M; Simard J; Symmons D; Watson K; Zink A
Rheumatology (Oxford); 2011 Jan; 50(1):146-51. PubMed ID: 20861148
[TBL] [Abstract][Full Text] [Related]
12. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan.
Nakajima A; Saito K; Kojima T; Amano K; Yoshio T; Fukuda W; Inoue E; Taniguchi A; Momohara S; Minota S; Takeuchi T; Ishiguro N; Tanaka Y; Yamanaka H
Mod Rheumatol; 2013 Sep; 23(5):945-52. PubMed ID: 23073692
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.
Costa L; Caso F; Del Puente A; Di Minno MN; Peluso R; Scarpa R
J Rheumatol; 2016 Dec; 43(12):2149-2154. PubMed ID: 27633825
[TBL] [Abstract][Full Text] [Related]
14. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
[TBL] [Abstract][Full Text] [Related]
15. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis.
Luo X; Deng C; Fei Y; Zhang W; Li Y; Zhang X; Zhao Y; Zeng X; Zhang F
Semin Arthritis Rheum; 2019 Feb; 48(4):626-631. PubMed ID: 29929736
[TBL] [Abstract][Full Text] [Related]
16. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
17. Mortality in psoriatic arthritis: Risk, causes of death, predictors for death.
Elalouf O; Muntyanu A; Polachek A; Pereira D; Ye JY; Lee KA; Chandran V; Cook RJ; Gladman DD
Semin Arthritis Rheum; 2020 Aug; 50(4):571-575. PubMed ID: 32454305
[TBL] [Abstract][Full Text] [Related]
18. Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study.
Ballegaard C; Højgaard P; Dreyer L; Cordtz R; Jørgensen TS; Skougaard M; Tarp S; Kristensen LE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):592-599. PubMed ID: 28772007
[TBL] [Abstract][Full Text] [Related]
19. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
20. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.
Mariette X; Matucci-Cerinic M; Pavelka K; Taylor P; van Vollenhoven R; Heatley R; Walsh C; Lawson R; Reynolds A; Emery P
Ann Rheum Dis; 2011 Nov; 70(11):1895-904. PubMed ID: 21885875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
